An Open-Label, Multinational, Multicenter, Phase IIIb Study With Subcutaneous Administration of Trastuzumab in Patients With HER2-Positive Early Breast Cancer to Evaluate Patient Satisfaction
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 30 Jun 2017
At a glance
- Drugs Trastuzumab (Primary) ; Carboplatin; Docetaxel; Doxorubicin; Paclitaxel
- Indications Adenocarcinoma; Early breast cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Roche
- 22 Jun 2017 Planned End Date changed from 30 Nov 2018 to 5 Dec 2018.
- 22 Jun 2017 Planned primary completion date changed from 30 Nov 2018 to 5 Dec 2018.
- 30 Mar 2017 Planned End Date changed from 1 Sep 2018 to 30 Nov 2018.